Pricing, Politics and AI To Take Center Stage in 2024

Not surprisingly, geopolitical and macroeconomic themes continue to play major roles in the market. As interest rates are expected to fall in 2024, and the industry sees more successful public offerings, the potential is there for investment dollars to return to biopharma. However, with the industry seeing increased regulatory activity and given this is an election year, optimism is conservative at best. Kranjac explained that the election is one of the wild cards the industry is facing. “The variable impact that is difficult to predict is the election in 4Q and its effect on the economy and the industry.” She also stated that startups had more realistic expectations this year, but some were feeling strained in current cash positions.